This trial will evaluate the safety, tolerability and effect of ATI-502 Topical applied twice daily in 24 adult subjects (12 male, and 12 female) with androgenetic alopecia. This 30-week trial will be conducted at 3 investigational centers within
JAK signaling has been implicated in maintaining the hair cycle in its resting phase (telogen) in mice. Treatment of mouse telogen skin with topical JAK inhibitors prompts telogen follicles to enter the active growth phase (anagen). Hair loss disorders, such as AGA, in which the hair follicles are arrested in telogen phase, may be responsive to treatment with topical JAK inhibitors to promote their entry into anagen, and thus result in the initiation of hair growth.1
“This trial is the first step in evaluating the potential clinical benefit of ATI-502 topical solution in treating patients with AGA, or male/female pattern baldness,” said Dr.
About Androgenetic Alopecia
Androgenetic alopecia (AGA), also known as male pattern baldness or female pattern hair loss, is the most common form of hair loss.2 The condition may affect up to 70% of men and 40% of women, beginning at some point in their adult lives.3 Male pattern baldness usually involves hairline recession and balding of the highest point of the head, while female pattern hair loss tends to manifest as thinning hair over the top of the scalp. Susceptibility to AGA is largely determined by genetics, though environmental factors may play a minor role. Affected individuals can be highly motivated to seek treatment, due to negative image perceptions.3 Currently available treatment procedures and medications are not optimal for some patients for various reasons, such as adverse reactions and contraindications. There is an unmet need for an additional safe and effective treatment option for AGA.
1 S. Harel,
2 Ghanaat M, Types of Hair Loss and Treatment Options. South Med J. 2010;103(9):917-921.
3 http://www.skintherapyletter.com/alopecia/promising-therapies/. Last accessed
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris’ clinical development of its JAK inhibitor drug candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended
Senior Vice President
Corporate Strategy/Investor Relations
Source: Aclaris Therapeutics, Inc.